40 / 86
0,0
0,2
0,4
0,6
0,8
1,0
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45
Eribulin
Dacarbazine
Secondary Endpoint PFS
Eribulin 228
79
41
27
16
9
5
2
1
0
Dacarbazine 224
63
27
14
6
4
2
1
1
0
Patients at Risk:
Schöffski P, et al. Presented at ASCO 2015 Annual Meeting, Chicago IL, June 3-7, 2015:abstr LBA10502
Eribulin Dacarbazine
Median (mos)
2.6
2.6
HR (95% CI)
0.877 (0.710-1.085)
Stratified
P
-value
0.2287
Survival Probability
Survival Time (mos)